Send to

Choose Destination
Crit Rev Oncol Hematol. 2014 Aug;91(2):142-58. doi: 10.1016/j.critrevonc.2014.02.002. Epub 2014 Feb 16.

A rationale for chemoradiation (vs radiotherapy) in salivary gland cancers? On behalf of the REFCOR (French rare head and neck cancer network).

Author information

Radiation Oncology, CHRU, Besancon 25030, France; CHBM, Montbéliard 25209, France.
Medical Oncology, APHP CHU Pitié Salpétrière, Paris75013, France.
Radiology, Centre Antoine Lacassagne, Nice 06189 France.
Head and Neck Surgery, APHP CHU Tenon, Paris 75020, France.
Pathology, Institut Gustave Roussy, Villejuif 94000, France.
Clinical Oncology, Faculty of Medicine, Sohag University, Egypt.
Maxillo-Facial Surgery, CHU d'Amiens, 80000 France.
Head and Neck Surgery, CHU de Grenoble, 38000 France.
Head and Neck Surgery, Institut Gustave Roussy, Villejuif 94000, France.
Radiation Oncology, Centre Antoine Lacassagne, Nice 06200, France. Electronic address:



Salivary gland carcinomas constitute a heterogeneous group of tumors, with over 20 histological subtypes of various prognoses. The mainstay of treatment is surgery, with radiotherapy advocated for unresectable disease or postoperatively in case of poor prognostic factors such as high grade, locally advanced and/or incompletely resected tumors. Concurrent chemotherapy is sometimes advocated in routine practice based on criteria extrapolated from squamous cell carcinomas of the head and neck, on radioresistance of salivary gland tumors and on results obtained in the metastatic setting. The aim of this review was to identify situations where chemotherapy is advocated.


A search of literature was performed with the following key words: parotid, salivary gland, neoplasm, cancer, malignant tumor, chemoradiation, chemotherapy, radiotherapy and treatment. Case report and studies published before 2000 were not included.


Platinum-based regimens were the most frequent. Other regimens were reported and seemed dependent on histology. The level of evidence for the concurrent delivery of chemotherapy with radiation therapy is supported by a low level of evidence. Prescribing chemotherapy mostly relies on poor prognostic factors similar to those used to indicate high dose radiotherapy. Protocols vary with histology.


The rationale for adding chemotherapy to radiotherapy remains to be demonstrated prospectively. Although the type of systemic treatments used may be adapted on histology, the strongest rationale remains in favor of cisplatin.


Adenoid cystic carcinoma; Cancer; Chemotherapy; Histology; Radiation therapy; Rare; Salivary gland; Survival

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center